Half-sandwich
complexes of iridium(III) are currently being developed
as anticancer drug candidates. In this context, we introduce IrBDP for which the C^N chelating phenyloxazoline ligand carries
a fluorescent and lipophilic BODIPY reporter group, designed for intracellular
tracking and hydrophobic compartment tropism. High-resolution analysis
of cells cultured with IrBDP showed that it quickly permeates
the plasma membrane and accumulates in the mitochondria and endoplasmic
reticulum (ER), generating ER stress, dispersal of the Golgi apparatus,
cell proliferation arrest and apoptotic cell death. Moreover, IrBDP forms fluorescent adducts with a subset of amino acids,
namely histidine and cysteine, via coordination of
N or S donor atoms of their side chains. Consistently, in
vivo formation of covalent adducts with specific proteins
is demonstrated, providing a molecular basis for the observed cytotoxicity
and cellular response. Collectively, these results provide a new entry
to the development of half-sandwich iridium-based anticancer drugs.